Droisys Life Science Division today unveiled a suite of e-business strategy services designed to help life sciences companies to avoid drug-development bottlenecks caused by breakthroughs in genetic research. These new services leverage the capabilities of the Web and other emerging technologies to help life science firms achieve R&D excellence and bring new drugs to market faster.

Exponential gains in understanding gene structure and function have created many opportunities to target diseases with new drugs, but the industry is not prepared for the massive amounts of data these gains generate or the number of potential new drugs entering development. Development bottlenecks are increasing because companies have been slow to adopt enabling technologies, and many lack focus or methods to achieve consistent first-pass quality.

Being veterans in the Pharmaceutical industry, Droisys consultants understand its complex issues and are offering advanced solutions with their technology partners.. This combination of deep industry expertise and best technology will help clients realize the potential of the Internet and emerging technologies to accomplish more with the same or fewer resources.

In addition to embracing new technology, companies need to reexamine other practices that create bottlenecks, said Hills. These include lack of clear priorities within development pipelines; information voids that lead to poor resource utilization; handoff processes that create extra work; and processes designed to fix rather than avoid poor initial quality, such as those employed in clinical trial data collection.